What's in the pipeline?

Come and find out what we have in the pipeline and explore those indications where our technology is set to have the greatest clinical benefit.

Active ingredient
Mechanism
Indication
Pre-clinical discovery
Pre-clinical development
Phase I/IIa
Phase IIb
Phase III
Status

allo-APZ2 1

Anti-inflammation

RDEB a b d

In set up

allo-APZ2 1

Anti-inflammation

Non-healing chronic venous wounds (CVU) 4

Recruiting

allo-APZ2 1

Anti-inflammation

Non-healing diabetic foot ulcers (DFU)

In set up

LSC2 3

Regeneration

LSCD a b c

On hold

APZ2 2

Anti-inflammation

Non-healing chronic venous wounds (CVU)

Closed

allo-APZ2 1

Anti-inflammation

ACLF

Closed


1 Allogeneic ABCB5-positive mesenchymal stem cells
2 Autologous ABCB5-positive mesenchymal stem cells
3 Allogeneic ABCB5-positive limbal stem cells
4 Marketing authorization in Germany granted for AMESANAR®

a Orphan Drug Designation FDA
b Orphan Drug Designation EMA
c Fast Track Designation FDA
d Pediatric Investigation Plan (PIP) approved by PDCO (EMA)

© 2021 RHEACELL. All rights reserved.